ACA
APLS

Apis Capital Advisors’s Apellis Pharmaceuticals APLS Stock Holding History

Apis Capital Advisors’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-192,000
Closed -$4.82M – 54
2025
Q4 		$4.82M Buy
+192,000
New +$4.5M 0.84% 30

Other funds holding APLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Apis Capital Advisors's APLS Position: Q1 2026 in Review

Apis Capital Advisors sold out of Apellis Pharmaceuticals (APLS) in Q1 2026, closing a stake of 192,000 shares — an estimated $4.82M sold.

Apis Capital Advisors first reported a position in APLS in Q4 2025 and held it in 1 quarter. The position peaked at $4.82M in Q4 2025. 323 funds tracked by Wall St. Rank hold APLS as of Q1 2026.

  • Apis Capital Advisors reported no remaining Apellis Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Apis Capital Advisors sold 192,000 Apellis Pharmaceuticals shares in Q1 2026, an estimated $4.82M.
  • Apis Capital Advisors first reported a position in Apellis Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Apis Capital Advisors's Apellis Pharmaceuticals position peaked at $4.82M in Q4 2025.
  • 323 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q1 2026.

Based on Apis Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.